The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.
May 1st 2024
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
MM-398 Receives Priority Review for Advanced Pancreatic Cancer
The FDA has assigned a priority review designation to MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following treatment with a gemcitabine-based therapy.
Ramucirumab HCC Data Published Amid Launch of Second Phase III Trial
Second-line treatment with ramucirumab did not improve overall survival compared with placebo in the full population of patients with advanced hepatocellular carcinoma examined in the phase III REACH study.
Panitumumab Improves OS Versus Supportive Care in Phase III mCRC Trial
Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.
PEGPH20 Combination Doubles PFS in HA-High Pancreatic Cancer
The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.
Selective Internal Radiation Therapy Effective in Some Patients With mCRC
Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.
Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer
June 10th 2015Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.